Patient-reported outcome (PRO)-based symptom assessment in patients with advanced lung cancer receiving first-line combination immunotherapy: a protocol for a multicenter, prospective, observational study
Abstract Background Immunotherapy is currently applied in the first-line treatment regimens for numerous advanced cancers, especially advanced lung cancer. Immune-related adverse events (irAEs) resulting from immunotherapy can vary in severity and cause a substantial symptom burden to patients. Howe...
Main Authors: | Yuanle Deng, Han Hu, Rong Jia, Wei Dai, Dengfeng Wang, Purong Zhang, Peng Zhang, Kai Cheng, Jianning Tang, Yan Wen, Xiang Zhou, Qiuling Shi, Zhujuan Xiong, Jin Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-05-01
|
Series: | BMC Pulmonary Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12890-023-02432-5 |
Similar Items
-
Predictive Role of Prior Radiotherapy and Immunotherapy-Related Adverse Effects in Advanced NSCLC Patients Receiving Anti-PD-1/L1 Therapy
by: Jeong Uk Lim, et al.
Published: (2021-08-01) -
Analysis of the efficacy and safety of immunotherapy in advanced thymoma patients
by: Yue Hao, et al.
Published: (2023-03-01) -
Adverse Events of Oncologic Immunotherapy and Their Management
by: Fedricker Diane Barber
Published: (2019-01-01) -
Understanding the Toxicity of Cancer Immunotherapies: Use of Patient-Reported Outcomes
by: Tito R Mendoza
Published: (2018-07-01) -
Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases
by: Jean-Matthieu L’Orphelin, et al.
Published: (2021-09-01)